Immunohistochemistry (IHC) Global Market Report 2024

The immunohistochemistry (ihc) market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historical period can be attributed to several factors, including increased clinical adoption of immunohistochemistry (IHC), industry standardization practices, expansion in cancer research, the automation of laboratory processes, and advancements in clinical diagnostics.

The immunohistochemistry (ihc) market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to factors such as the entry of new players into the market, increased demand in drug development, integration of immunohistochemistry (IHC) in biomedical research, expanding applications in diagnostics, and the ongoing trends of automation and digitalization in laboratory processes. Major trends expected in the forecast period include the adoption of multiplex IHC techniques, integration with digital pathology systems, improvements in antibody specificity, increased automation and standardization of IHC processes, and the application of IHC in biomarker discovery.

The immunohistochemistry (IHC) market is anticipated to witness growth due to the increasing prevalence of chronic diseases. Chronic diseases, lasting for extended periods and typically manageable but not curable, include conditions such as cancer and cardiovascular disorders. Immunohistochemistry is crucial in diagnosing these diseases, offering advantages such as specificity, sensitivity to detect specific antigens, and rapid results. In 2022, the Centers for Disease Control and Prevention reported that approximately 37.3 million people in the United States, accounting for 11.3% of the population, have diabetes, emphasizing the role of immunohistochemistry in addressing the rising burden of chronic diseases.

The growth of the immunohistochemistry (IHC) market is further driven by the increasing demand for personalized medicines. Personalized medicine tailors medical decisions and interventions based on individual patients' unique genetic, environmental, and lifestyle characteristics. Immunohistochemistry plays a significant role in this context, detecting specific protein markers crucial for accurate tumor classification and diagnosis. The Personalized Medicine Coalition projected that over 75,000 genetic testing products and 300 personalized medicines will be available for various diseases, reinforcing the pivotal role of immunohistochemistry in advancing personalized medicine.

Technological advancement stands out as a key trend in the immunohistochemistry (IHC) market, with major companies focusing on developing advanced products. For example, Akoya Biosciences introduced the Opal Multiplex Detection Kits, utilizing Opal multiplex technology for detecting multiple biomarkers in tissue sections. These kits offer phenotypic scoring, signal amplification, low sample and reagent consumption, and the ability to measure 3 to 8 IHC targets and nuclear stains.

Major companies in the immunohistochemistry (IHC) market are introducing innovative platforms, such as automated staining platforms, to enhance IHC applications. These platforms automate the staining process of tissue sections with antibodies, improving efficiency and accuracy. Biocare Medical LLC launched the ONCORE Pro Automated Slide Staining System in January 2021, providing a fully automated platform for IHC and in-situ hybridization (ISH) applications. The system can process up to 36 slides in a single run, enabling high-throughput slide processing for diagnostic laboratories.

In October 2021, StageBio, a US-based company specializing in immunohistochemistry (IHC), acquired TPL Path Labs. This acquisition aims to strengthen StageBio's product portfolio in IHC, clinical histopathology, and molecular pathology, enhancing its market position. TPL Path Labs, based in Germany, operates in the field of immunohistochemistry (IHC).

Major companies operating in the immunohistochemistry (ihc) market report are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, The Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Becton Dickinson and Company, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., BioVision Inc., PHC Holdings Corporation, Abbott Laboratories, Leica Biosystems, Vector Laboratories, Indivumed GmbH, Qritive, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech, Histologix Ltd., NeoGenomics Laboratories Inc.

North America was the largest region in the immunohistochemistry (IHC) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (ihc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunohistochemistry (ihc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main products associated with immunohistochemistry (IHC) include antibodies, equipment, reagents, and kits. Antibodies are proteins produced by the immune system to neutralize harmful antigens, and in the context of IHC, they are employed to detect the specific location of proteins or antigens for diagnostic purposes. The applications of IHC span diagnostics, drug testing, and other related areas, with end-users including hospitals, diagnostic laboratories, research institutes, and others.

The immunohistochemistry (IHC) market research report is one of a series of new reports that provides immunohistochemistry (IHC) market statistics, including immunohistochemistry (IHC) industry global market size, regional shares, competitors with a immunohistochemistry (IHC) market share, detailed immunohistochemistry (IHC) market segments, market trends and opportunities, and any further data you may need to thrive in the immunohistochemistry (IHC) industry. This immunohistochemistry (IHC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.